Biopharmaceutical manufacturers are transforming mRNA production lines into modular facilities capable of switching targets within days. This operational flexibility is reshaping clinical trial execution for targeted cancer vaccines.
Microfluidic Advances
New microfluidic mixing technologies allow precise encapsulation of RNA payloads into lipid nanoparticles at scale. The process reduces active ingredient wastage by standardizing particle size distribution.
Supply Chain Decentralization
Firms are building localized manufacturing hubs near major medical centers, cutting cold-chain distribution complexity for personalized therapeutics requiring rapid turnarounds.